Professional Documents
Culture Documents
0000000000005804
EDITORIAL
®
Prof. Birbaumer
Neurology 2018;0:1-2. doi:10.1212/WNL.0000000000005804 niels.birbaumer@
uni-tuebingen.de
An early goal for brain-computer interfaces (BCIs) is to provide people with tetraplegia and RELATED ARTICLE
severe speech impairments with a restored ability to communicate, using only brain signals to
drive a computer interface. The most extensively researched BCIs are those that use scalp-based Independent home use of
EEG recordings; over the past 30 years, these EEG-BCIs have been developed and tested with a brain-computer interface
both healthy, uninjured people and people with paralysis (e.g., due to ALS).1,2 While there have by people with
been many reports of single or a few individuals with paralysis who have used EEG-BCIs for amyotrophic lateral
communication, formal clinical trials for efficacy have been missing. sclerosis
Page 118
In this issue of Neurology®, Wolpaw et al.3 report the first prospective, multisite, pivotal clinical
trial of an EEG-BCI. The Wadsworth BCI, which consists of an EEG cap, a power-conditioned
amplifier, a laptop, and a monitor, was set up by the research team at participants’ homes. With
only occasional remote support from the researchers, participants, veterans with ALS, who
could use the technology were permitted to do so for up to 18 months. Frequency of use,
communication rate, and quality-of-life measures were assessed. The authors deserve great
credit for planning and executing this important study.
The results are, as noted in the article, “complicated.” After 42 patients provided consent, of
whom 39 met inclusion criteria, 2 withdrew consent and another 9 (25%) could not use the
EEG-BCI during screening assessments. All participants had some method of communication;
that is, none had complete locked-in syndrome (CLIS) and thus all had some method of
communication, including other assistive technologies such as eye-gaze systems. Of the
remaining 27 available participants who had devices placed in the home, only 14 completed up
to an additional month needed for patient and caregiver training. The reasons for this attrition
included losing interest, disease progression, and death. Four additional participants withdrew
from the trial (in addition to 2 deaths), leaving 8 of 39 participants using the system at study
end. For the 14 (≈33%) recruited participants (in a intention-to-treat analysis) who could use
the system at home for long enough to evaluate it (2–17 months), objective performance as
a communication system was unimpressive. The system could be used on only ≈57% of days,
the remainder being precluded by declining health, absence of caregiver, work, or travel. Of
those available days, it was used on average 2 d/wk for 1.3 h/d. And over those 1.3 hours, users
could make ≈3 selections (letters, words with word prediction, icons, etc.) per minute with
≈73% selection accuracy. To enable this 1.3 hours, caregivers needed to spend ≈30 minutes
preparing the system or placing/removing/cleaning the cap. The communication rate enabled
by this EEG-BCI was similar to that in the recent report of a fully implanted, subdural (elec-
trocorticographic) BCI used by a person with ALS and locked-in syndrome at home.4
It would be easy to conclude that this is another frustrating trial result in ALS, but there is
a silver (silver-chloride) lining. Seven of 8 participants kept the BCI at the end of the study, an
unambiguous vote by those 7 participants that the system was viewed as having either current or
future value. The system itself was nearly always in good working order, which is no small feat
for an assistive communication technology. The authors conclude, “The Wadsworth BCI home
From the Wyss Center for Bio and Neuroengineering (N.B.), Geneva, Switzerland; Faculty of Medicine (N.B.), Institute of Medical Psychology and Behavioral Neurobiology, University
of Tuebingen, Germany; School of Engineering and Carney Institute for Brain Science (L.R.H.). Brown University, Providence, RI; Center for Neurotechnology and Neurorecovery
(L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston; and VA RR&D Center for Neurorestoration and Neurotechnology (L.R.H.),
Providence Veterans Affairs Medical Center, RI.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
Updated Information & including high resolution figures, can be found at:
Services http://n.neurology.org/content/early/2018/06/27/WNL.0000000000005
804.full
Subspecialty Collections This article, along with others on similar topics, appears in the
following collection(s):
All clinical neurophysiology
http://n.neurology.org/cgi/collection/all_clinical_neurophysiology
All Neuromuscular Disease
http://n.neurology.org/cgi/collection/all_neuromuscular_disease
EEG; see Epilepsy/Seizures
http://n.neurology.org/cgi/collection/eeg_see_epilepsy-seizures
Evoked Potentials/Visual
http://n.neurology.org/cgi/collection/evoked_potentials-visual
Permissions & Licensing Information about reproducing this article in parts (figures,tables) or in
its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions
Reprints Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise
Neurology ® is the official journal of the American Academy of Neurology. Published continuously since
1951, it is now a weekly with 48 issues per year. Copyright © 2018 American Academy of Neurology. All
rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.